Patent Grant
7919483
This invention relates to the treatment of acne vulgaris, commonly known simply as “acne.” Acne is a disease of the skin in which the pilosebaceous structures of the skin become inflamed, leading to the formation of comedones, pustules and nodules. Acne can lead to permanent scarring in severe cases.
It is generally believed that acne arises when hyperkeratosis of the pilosebaceous structure wholly or partially blocks the opening of the structure, resulting in comedones filled with sebum, keratin, and Propionibacterium acnes. These lesions are commonly identified as acne. P. acnes naturally occurs in normal skin, but is especially and characteristically present in acne lesions. It is believed that metabolic byproducts and waste from P. acnes within the pilosebaceous structures cause or contribute to the inflammation of acne lesions.
Conventional acne treatments have taken many forms. Topical keratolytic agents, such as salicylic acid are sometimes used. Keratolytic agents are thought to encourage the opening up of blocked pilosebaceous structures, thereby reducing conditions that are favorable to inflammation. Benzoyl peroxide, an anti-microbial, remains a popular and effective treatment. Topical antibiotics, such as clindamycin, which are effective against P. acnes, have also been used with a view towards preventing the formation of metabolic byproducts from this organism. Topical retinoids such as tretinoin have also been used in the treatment of acne.
Systemic (i.e. non-topical) treatments for acne include the use of oral antibiotics in more serious cases. These treatments are directed towards the reduction in the amount P. acnes in the skin, especially the pilosebaceous structures, and seek to reduce the inflammation caused by waste materials and metabolic byproducts from these organisms. Tetracycline antibiotics are most commonly used for this purpose. These include tetracycline, minocycline and doxycycline. Erythromycin is also sometimes used.
Standard oral minocycline therapy for acne in pediatric patients calls for the administration of a 4 mg/kg initial loading dose, and a 2 mg/kg dose every 12 hours thereafter. This results in a dose of 6 mg/kg on the first day of treatment and a 4 mg/kg dose each day thereafter. In adults, a 200 mg initial dose is followed by a 100 mg dose every 12 hours thereafter. In a typical patient, this results in about a 4.5 mg/kg dose on the first day of treatment, and 3.0 mg/kg dose each day thereafter.
In cases where acne does not respond to oral antibiotic treatment, oral isotretinoin is sometimes used. While effective, isotretinoin is also powerfully teratogenic, and women of childbearing age are required to use multiple methods of contraception while taking the drug.
While oral tetracycline antibiotics remain a highly favored and widely used treatment for more serious cases of acne, it is not without side effects. Vestibular side effects, including extreme dizziness and concomitant nausea, can be so severe as to result in discontinuance of tetracycline therapy. Long term use can sometimes result in vaginal candidisis, esophageal erosions and in antibiotic resistant infections.
Some recent research has indicated that very low doses of oral tetracycline can result in some improvement of acne even though the dose of tetracycline is too low to have an antibiotic effect. This observation has been attributed to an anti-inflammatory effect of tetracycline compounds. This effect has been reported to have been observed even where a chemically modified tetracycline that have no antibiotic properties are used. The use of tetracycline antibiotics at a dose too low to have an antibiotic effect or the use of modified tetracycline having no antibiotic properties as treatments for acne has never been approved by any drug regulatory agency.
According to the present invention, a method is provided for the treatment of acne in which an antibiotically effective dose of an oral tetracycline, such as minocycline, is provided. This dose is approximately 1 milligram per kilogram of body weight (1 mg/kg), without an initial loading dose of antibiotic. This antibiotic dosing regimen has been found to be as effective as a conventional dosing regimen incorporating a significant initial loading dose and higher subsequent doses. However, the dosing method of the current invention produces far fewer side effects.
In another aspect of this invention, the oral tetracycline is provided in a dosage form that provides for the continued release of the antibiotic between doses, as opposed to an immediate or nearly immediate release of the drag.
According to the present invention, acne vulgaris is treated by the use of an oral tetracycline antibiotic, preferably minocycline. This antibiotic is administered in an antibiotically effective amount of approximately 1.0 milligram per kilogram of body weight per day (1.0 mg/kg/day). While this may be accomplished by the use of divided doses, it is preferred that the tetracycline antibiotic be delivered in a single daily dose. This treatment regime is initiated without a loading dose, and is continued until resolution or substantial resolution of the patient's acne. The course of treatment typically lasts 12 to up to 60 weeks, but will be adjusted according to the disease status and other medical conditions of each patient in the exercise of ordinary good clinical judgment by the patient's health care provider.
Controlled, double-blinded studies were undertaken to determine the effectiveness of this invention. Treatment of 473 patients with acne was undertaken according to the present invention. Placebos were provided to 239 patients. The effectiveness of the invention in treating acne vulgaris is shown in Table 1.
While effective as a treatment for acne, this resulted in almost no side effects above those observed with a placebo, as shown in Table 2.
The effectiveness of this invention can be seen by comparing the above efficacy data with published data on the effectiveness of conventional tetracycline treatments for acne in the reduction of total acne lesions and in the reduction of inflammatory lesions. See, e.g. Hersel & Gisslen, “Minocycline in Acne Vulgaris: A Double Blind Study,” Current Therapeutic Research, 1976.
Because of the variations in body weight encountered in clinical practice, in the actual practice of this invention it is not practical to provide every patient with exactly 1 mg/kg/day of oral tetracycline antibiotic. However, it is acceptable to approximate this dose by providing the patient with from 0.5 to 1.5 mg/kg/day although from 0.7 to 1.3 mg/kg/day is preferred, and 1.0 mg/kg/day is ideal.
While it can be effective to provide the oral tetracycline antibiotic in divided doses taken over the course of a day (e.g. twice or three times a day), it is preferable to provide the oral tetracycline antibiotic in a dosage form that releases the antibiotic slowly during the course of a day so that once-a-day dosing is possible. While delayed release dosage forms are known in the art, the formulation of them is far from predictable and the selection of a specific delayed release formulation is accomplished more by trial and error than by mathematical prediction based on known properties of delay release agents. No delayed release product useful in the present invention has been known heretofore.
It has been discovered that the ratio of fast dissolving carriers to slow dissolving carriers in the core caplet is important in obtaining a dissolution profile that enables once-a-day dosing in accordance with the present invention. By keeping the ratio of these components within a certain range, one may obtain this result.
The fast dissolving carrier is any binder, vehicle, or excipient that quickly dissolves in an aqueous physiological medium, such as gastric fluid, thereby tending to quickly release the active ingredient. Lactose, its salts and hydrates are good examples of such components. It has been observed that sometimes a portion of the fast dissolving components are formulated in a manner that results in the complete or partial encapsulation or inclusion or coating of these fast-dissolving materials in granules of slow-dissolving materials. These encapsulated materials are excluded from the calculation of the above mentioned ratio of fast-dissolving to slow dissolving components.
A slow dissolving carrier is any binder, vehicle, or excipient that dissolves slowly over the course of hours and perhaps a day, thereby slowing the release of the active ingredient. Examples of such components are polyvinyl pyrrolidone, polyvinyl acetate, microcrystalline cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, or waxy or lipid-based tableting agents such as magnesium stearate or calcium stearate. Outer “enteric” coatings are excluded from this amount when calculating the above-mentioned ratio.
Insoluble carriers are binders, vehicles, or excipients that are practically insoluble in physiological fluids, such as gastric fluid, and includes compounds, such as silicon dioxide and talc.
While the exact formulation of these dosage forms can vary, it has been observed that it is advantageous to formulate them so that the ratio of fast dissolving carriers to slow dissolving carriers is from 0.30 to 0.50, and preferably from 0.35 to 0.45. A ratio of about 0.36 to 0.40 is particularly preferable.
Dosage forms, such as capsules, tablets, and caplets that release 25 to 52% of the antibiotics within 1 hour, 53 to 89% in 2 hours, and at least 90% within 4 hours are suited to the once-a-day dosage regimen contemplated by the current inventories. More preferably, 30 to 52% of the antibiotic is released within 1 hour, 53 to 84% within 2 hours, and at least 85% within 4 hours.
Alternatively, the oral tetracycline antibiotic may be delivered in a dosage form that releases the antibiotic in such a way that the maximum blood concentration of the antibiotic (Cmax) is reached at about 3.5 hours after administration (Tmax). In actual practice of the invention, the Cmax should be reached between 2.75 and 4.0 after administration, more preferably between 3.0 and 3.75 after administration.
As examples of such a once-a-day formulation, one may use the following:
Each of these components is combined in a conventional fashion, compressed in a tabletting apparatus, and then provided in a conventional manner with a suitable coating, such as, without limitation Opadry II and optional coloring.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3932615 | Ito et al. | Jan 1976 | A |
| 3957980 | Noseworthy | May 1976 | A |
| 3966922 | Okamoto et al. | Jun 1976 | A |
| 4086332 | Armstrong | Apr 1978 | A |
| 4126680 | Armstrong | Nov 1978 | A |
| 4369172 | Schor et al. | Jan 1983 | A |
| 4376118 | Daher et al. | Mar 1983 | A |
| 4443442 | Skillern | Apr 1984 | A |
| 4701320 | Hasegawa et al. | Oct 1987 | A |
| 4764377 | Goodson | Aug 1988 | A |
| 4792448 | Ranade | Dec 1988 | A |
| 4806529 | Levy | Feb 1989 | A |
| 4837030 | Valorose, Jr. et al. | Jun 1989 | A |
| 4925833 | McNamara et al. | May 1990 | A |
| 4935411 | McNamara et al. | Jun 1990 | A |
| 4935412 | McNamara et al. | Jun 1990 | A |
| 4960913 | Szalay et al. | Oct 1990 | A |
| 5007790 | Shell | Apr 1991 | A |
| 5122519 | Ritter | Jun 1992 | A |
| 5167964 | Muhammad et al. | Dec 1992 | A |
| 5188836 | Muhammad et al. | Feb 1993 | A |
| 5202128 | Morella et al. | Apr 1993 | A |
| 5209978 | Kosaka et al. | May 1993 | A |
| 5211958 | Akkerboom et al. | May 1993 | A |
| 5217493 | Raad et al. | Jun 1993 | A |
| 5230895 | Czarnecki et al. | Jul 1993 | A |
| 5262173 | Sheth et al. | Nov 1993 | A |
| 5277916 | Dwyer et al. | Jan 1994 | A |
| 5283065 | Doyon et al. | Feb 1994 | A |
| 5300304 | Sheth et al. | Apr 1994 | A |
| 5324751 | DuRoss | Jun 1994 | A |
| 5348748 | Sheth et al. | Sep 1994 | A |
| 5413777 | Sheth et al. | May 1995 | A |
| 5459135 | Golub et al. | Oct 1995 | A |
| 5518730 | Fuisz | May 1996 | A |
| 5554654 | Yu et al. | Sep 1996 | A |
| 5582837 | Shell | Dec 1996 | A |
| 5665776 | Yu et al. | Sep 1997 | A |
| 5674539 | Tomas | Oct 1997 | A |
| 5776489 | Preston et al. | Jul 1998 | A |
| 5780049 | Dickner et al. | Jul 1998 | A |
| 5800836 | Morella et al. | Sep 1998 | A |
| 5814331 | Holen | Sep 1998 | A |
| 5834450 | Su | Nov 1998 | A |
| 5855904 | Chung et al. | Jan 1999 | A |
| 5908838 | Gans | Jun 1999 | A |
| 5972389 | Shell et al. | Oct 1999 | A |
| 6087382 | Bonner, Jr. et al. | Jul 2000 | A |
| 6120803 | Wong et al. | Sep 2000 | A |
| 6165513 | Dansereau et al. | Dec 2000 | A |
| 6165999 | Vu | Dec 2000 | A |
| 6194000 | Smith et al. | Feb 2001 | B1 |
| 6340475 | Shell et al. | Jan 2002 | B2 |
| 6340476 | Midha et al. | Jan 2002 | B1 |
| 6429204 | Golub et al. | Aug 2002 | B1 |
| 6455583 | Pflugfelder et al. | Sep 2002 | B1 |
| 6497902 | Ma | Dec 2002 | B1 |
| 6638922 | Ashley et al. | Oct 2003 | B2 |
| 6673843 | Arbiser | Jan 2004 | B2 |
| 6863830 | Purdy et al. | Mar 2005 | B1 |
| 6958161 | Hayes et al. | Oct 2005 | B2 |
| 7008631 | Ashley | Mar 2006 | B2 |
| 7211267 | Ashley | May 2007 | B2 |
| 20020015731 | Appel et al. | Feb 2002 | A1 |
| 20030082120 | Milstein | May 2003 | A1 |
| 20030130240 | Ashley | Jul 2003 | A1 |
| 20030139380 | Ashley | Jul 2003 | A1 |
| 20030199480 | Hayes et al. | Oct 2003 | A1 |
| 20030229055 | Ashley | Dec 2003 | A1 |
| 20040002481 | Ashley et al. | Jan 2004 | A1 |
| 20040115261 | Ashley | Jun 2004 | A1 |
| 20040127471 | Reisberg | Jul 2004 | A1 |
| 20040228912 | Chang et al. | Nov 2004 | A1 |
| 20050136107 | Patel et al. | Jun 2005 | A1 |
| 20050148552 | Ryan et al. | Jul 2005 | A1 |
| 20060293290 | Wortzman et al. | Dec 2006 | A1 |
| Number | Date | Country |
|---|---|---|
| 2025703 | Sep 1990 | CA |
| 2068366 | Nov 1992 | CA |
| 2090561 | Feb 1993 | CA |
| 0 184 389 | Jun 1986 | EP |
| 0 418 565 | Mar 1991 | EP |
| 0 558 913 | Sep 1992 | EP |
| 2414668 | Dec 2005 | GB |
| WO 9318755 | Sep 1993 | WO |
| WO 9811879 | Mar 1998 | WO |
| WO 9855107 | Dec 1998 | WO |
| WO 02080932 | Oct 2002 | WO |
| WO 03088906 | Oct 2003 | WO |
| WO 2004012700 | Feb 2004 | WO |
| WO 2004078111 | Sep 2004 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20060293290 A1 | Dec 2006 | US | |
| 20070225262 A2 | Sep 2007 | US |
